Radiologic assessment of benoxaprofen therapy in rheumatoid arthritis.

Abstract

Our study of 39 patients with rheumatoid arthritis suggests a trend for benoxaprofen therapy given over a prolonged period to retard the rheumatologic process when measured radiologically by both osseous defect and joint space narrowing rates. After a mean duration of 21 months, the progression of osseous defects (OD) and/or joint space narrowing (JSN) was decreased in 28 of 39 patients (72%) who qualified for this study. Fourteen patients (36%) had both OD and JSN rates decreased. An additional 8 patients had OD rate diminished alone and another 6 patients had JSN decreased alone. Clinical evaluation of benoxaprofen has previously revealed a low risk factor and an ability to improve clinical symptoms and signs. Because there is also a trend for this drug to retard or arrest radiologic progression, it becomes a promising agent for the long-term treatment of rheumatoid arthritis.

• Authors: G B Bluhm, D W Smith, W M Mikulaschek
• Journal: European journal of rheumatology and inflammation (Eur J Rheumatol Inflamm) Vol. 5 Issue 2 Pg. 186-97 ( 1982) ISSN: 0140-1610 [Print] England
• PMID: 7044795 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Anti-Inflammatory Agents
• Propionates
• benoxaprofen

Topics

• Anti-Inflammatory Agents (therapeutic use)
• Arthritis, Rheumatoid (diagnostic imaging, drug therapy)
• Clinical Trials as Topic
• Double-Blind Method
• Hand (diagnostic imaging)
• Humans
• Propionates (therapeutic use)
• Radiography
• Time Factors